source
- Safety concerns rise as Neurocrine's Prader-Willi drug linked to deaths and hospitalizationsPatient advocates and several experts are voicing increasing alarm over the safety profile of Neurocrine Biosciences' therapy for Prader-Willi syndrome. The drug, Vykat XR, received approval 18 mo…
- Novartis secures supplemental FDA approval to market repurposed antibiotic Lamprene in the USNovartis has obtained a supplemental approval from the U.S. Food and Drug Administration for its drug Lamprene, allowing it to be sold as an antibiotic. Lamprene, originally developed decades ago…